Alios BioPharma’s Corporate Venture Backers Ride RSV (And Hep C) To A Big Payday

The venture arms of Big Pharma have helped hold up early stage biotech funding the past few years. The acquisition of Alios BioPharma, announced Tuesday, could be the biggest win yet for that group. Alios, a South San Francisco, CA-based developer of antiviral drugs, went to Janssen Pharmaceuticals, a division of Johnson & Johnson (NYSE: JNJ), for $1.75 billion. That’s 24 times the amount of cash five investors put into the company across two rounds of financing.

Hey, check out all the research scientist jobs. Post your resume today!